Toutes les photos(1)

Documents

COO/COA

Y0000009

Fluphenazine enantate

Name: Fluphenazine enantate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl heptanoate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₉H₃₈F₃N₃O₂S

Numéro CAS:

2746-81-8

Poids moléculaire :

549.69

Code UNSPSC :

41116107

Nomenclature NACRES :

NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluphenazine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3

Clé InChI

LRWSFOSWNAQHHW-UHFFFAOYSA-N

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluphenazine enantate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1282026

Pictogrammes

GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H360

Conseils de prudence

P201 - P301 + P310 + P330

Classification des risques

Acute Tox. 3 Oral - Repr. 1A

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

[Effect of a single dose of some long-acting neuroleptics on the estrus cycle and the mammary gland of the rat].

J P Lanza et al.

Comptes rendus des seances de la Societe de biologie et de ses filiales, 173(4), 797-806 (1979-01-01)

The effects of two neuroleptics (pipotiazine and fluphenazine) and five long-acting neuroleptics (pipotiazine undecylenate and palmitate, fluphenazine enanthate and decanoate, fluopentixol decanoate) are tested in the rat, during an observation period of 20 to 40 days following only one injection

Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.

K Yamada et al.

Pharmacology, 24(3), 147-155 (1982-01-01)

The cataleptic state induced by the depot-type preparations of fluphenazine (FZ) was investigated in mice. Intramuscular injections of FZ-enanthate or FZ-decanoate produced a marked and long-lasting catalepsy, which was antagonized by trihexyphenidyl, biperiden and promethazine but not by l-dopa. These

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.

A C Altamura et al.

Psychopharmacology, 87(1), 30-33 (1985-01-01)

Seven outpatients already receiving neuroleptic drugs by depot intramuscular injections were treated in two consecutive 3-week periods with 25 mg fluphenazine doses as enanthate and decanoate esters in a double-blind crossover study. They were assessed for incidence of akinesia, involuntary

Pharmacotherapy and suicide risk in schizophrenia.

T P Hogan et al.

Canadian journal of psychiatry. Revue canadienne de psychiatrie, 28(4), 277-281 (1983-06-01)

The authors examined drug prescribing patterns and incidence of side effects in schizophrenic patients who committed suicide as compared with a matched control group. The groups did not differ in type of drug prescribed, though patients in the suicide group

Depot fluphenazine: risk/benefit ratio.

W M Glazer

The Journal of clinical psychiatry, 45(5 Pt 2), 28-35 (1984-05-01)

The risks and benefits associated with depot fluphenazine are reassessed by a review and critique of the literature, with an emphasis on controlled studies comparing depot to oral preparations. Specific gaps in our knowledge are noted and recommendations are made

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique